Time to Take Gout Seriously

Overall Program Agenda

Epidemiology and Pathogenesis of Gout

Overall Prevalence of Gout

Comorbidities of Gout

Pathophysiology of Gout

Hyperuricemia and Crystal Deposition

Natural Course of Disease

Conclusions

Guideline Recommendations for Diagnosis and Treatment of Gout

Key Points for Discussion

When to Initiate ULT

The Treat to Target Approach

Monitoring SUA Levels in Patients on ULT

Conclusions

Current and Emerging Treatment Options for Gout

Key Points for Discussion

EULAR Recommendations for ULT

Review of Currently Available ULT

Lesinurad Plus Allopurinol in Patients With Gout: CLEAR 1 and CLEAR2

Lesinurad Plus Febuxostat in Patients With Tophaceous Gout: CRYSTAL

Effect of Lower SUA on Tophi and Gout Flares: Pooled Analysis of CLEAR 1, CLEAR 2, and CRYSTAL

ULT in Development

Treating and Preventing Flares

Conclusions

Cardiovascular Risks and Complications in Patients With Gout

Increased Risk for CV Complications and Mortality in Patients With Gout

Risk for HF and Mortality Increases With Increasing SUA

Managing CV Risk in Patients With Gout

Managing CV Risk in Patients With Gout (cont)

Case Example: Presentation

Case Example: Management

Conclusions

Renal Complications in Patients With Gout

EULAR Recommendations for Patients With Impaired Renal Function

Treating Gout Patients With Renal Impairment in Clinical Practice

Monitoring Gout Patients With Renal Impairment in Clinical Practice

Case Example: Presentation

Case Example: Management

Conclusions

Best Practice for Managing Gout in Primary Care

Defining the Role of the PCP

Managing Patients With Gout in Primary Care

Barriers to Effective Management of Gout in Primary Care

Optimizing the Physician-Patient Relationship in Primary Care

When to Refer Patients With Gout for Specialty Consultation

Conclusions

Program Conclusions

Abbreviations

Abbreviations (cont)

Abbreviations (cont)